Shamburg News · 8-K filed Oct 14, 2026, 7:57 AM EDT
Akebia Therapeutics CCO Nicholas Grund to resign effective November 6, 2026
AKBA · Akebia Therapeutics, Inc.
- Leadership change
- Material agreement
- Materiality: medium
On October 7, 2026, Akebia Therapeutics, Inc. disclosed that Senior Vice President and Chief Commercial Officer Nicholas Grund notified the company of his decision to resign for personal reasons, effective November 6, 2026. On October 13, 2026, Mr. Grund and the company entered into a Consulting Agreement, effective as of the resignation date, to provide consulting and advisory services until April 30, 2027, paid at an hourly rate. The agreement may be terminated earlier by the company on at least 10 days' notice or by Mr. Grund on at least 30 days' notice.
Source: SEC EDGAR, Form 8-K, Item 5.02, accession 0001517022-26-000071.
Written from the filing by Shamburg Markets. Figures are as reported by the company.